|

|
|
|
|
| Company Spotlight |
| Abbott and Novo broaden access to semaglutide for advanced diabetes care across Asia Pacific |

Abbott, the global healthcare leader, and Novo, a global leader in treatments for serious chronic diseases, have announc...Read more
- 06 November 2026 News
|
|
| Company Spotlight |
| Japan's Nxera Pharma inks agreement worth $1.47 B with AbbVie for IBD drug |

Japan-based Nxera Pharma has announced that its subsidiary, Nxera Pharma UK, has entered into an exclusive global licens...Read more
- 06 November 2026 News
|
|
|
|
|
| World |
| Korea's IVI supports Minapharm for development of Bundibugyo ebolavirus vaccine |

|
South Korea-based International Vaccine Institute (IVI) has joined Bayer AG and the Coalition for Epidemic Preparedness ...Read more
- 06 November 2026 News
|
|
| Vietnam |
| NCCN and Viet Nam National Cancer Hospital expand collaboration to advance cancer care resources in Vietnam |

|
The National Comprehensive Cancer Network® (NCCN®) has announced the signing of a new agreement with the Vi...Read more
- 06 November 2026 News
|
|
|
|
|
|
| Company Spotlight |
| Boehringer Ingelheim and Sino Biopharma advance next-gen cancer therapies with $7 B deal |

|
Boehringer Ingelheim, headquartered in Germany, and China-based Sino Biopharmaceutical (together with its subsidiaries, ...Read more
- 06 November 2026 News
|
|
|
|
|
All you want to read on
|

|
|
This email has been sent to you in association with
www.biospectrumasia.com
Tell Us What You Think! Help us improve our newsletters. Send us your feedback!
© Copyright 2026 MM ACTIV. All rights reserved.
To Unsubscribe click here.
Disclaimer : Please remember – by opting-in you are still able to opt-out at any time, by simply replying to this email at digital@mmactiv.com and typing 'unsubscribe' in the 'subject' field of any future emails. We promise only to send emails that we believe you will find interesting, relevant and current. Your data will never be sold or shared with any third party, although we may communicate a message to you from a partner that we are in collaboration with.
|
|
|